** Morgan Stanley initiates coverage of drug development software provider Certara CERT.O with an "equal weight" rating
** "A key focus for the company is biosimulation, where Certara's platforms are designed to optimize drug design and testing" - Brokerage
** Morgan Stanley says CERT has a market-leading platform and generates strong recurring revenues with significant cross-selling opportunities
** Brokerage PT remains unchanged at $16, a ~39.3% upside on the stock's last close
** Five of 11 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $16 - LSEG data
** As of last close, stock up ~7.9% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。